• Improved Drug Safety Needs Better Data Before AI

    Bio-IT World | Applying artificial intelligence (AI) to fragmented and incomplete safety data cannot fill the gap left when the right information has not been captured during initial patient adverse event reporting. And yet, software vendors position the technology as a quick fix to safety data complexity. Although AI definitely has a role to play, it would be far better to use it to refine the data capture process.

    Jan 23, 2026

  • AI in Pharma: Progress Made, But Data Challenges Persist

    Bio-IT World | The pharmaceutical industry’s approach to artificial intelligence is maturing, with companies increasingly focused on innovation rather than mere efficiency gains. However, significant hurdles around data quality and workforce training continue to impede progress.

    Jan 20, 2026

  • 10x Genomics Positions Spatial Biology as Center Stage as AI Fuels New Wave of Customer Demand

    Bio-IT World | At the 44th Annual J.P. Morgan Healthcare Conference, 10x Genomics announced a strong ending to 2025. With great anticipation for 2026, 10x Genomics remains centered on their mission on accelerating understanding of biology to advance human health, particularly in the single-cell and spatial biology areas.

    Jan 14, 2026

  • Illumina at JPM 2026: Strong Q4, Clinical Growth, and BioInsight Launch

    Bio-IT World | Jacob Thaysen returned to the J.P. Morgan Healthcare Conference stage Tuesday with a message of momentum: Illumina is back to growth, and clinical sequencing is driving the train. In his third annual presentation as CEO, Thaysen unveiled preliminary fourth quarter results that exceeded expectations and introduced BioInsight, a new business unit aimed at accelerating drug discovery through AI-powered biological insights.

    Jan 13, 2026